Ieramlimab (LAG525) is a humanized IgG4 monoclonal antibody developed by Novartis that inhibits the interaction between LAG3 and MHC-II, as well as FGL-1, thereby suppressing tumor cell growth. This evidence concerns the gene FGL1 and neoplasm.